Skip to content

Comparative Evaluation Of The Efficacy Of Standard Market Preparation Tablet And Swayamguptadi Vati In The Management Of Klaibya (Erectile Dysfunction)

Comparative Evaluation of the efficacy of standard market preparation (Tablet) and swayamguptadivati in the management Of Klaibya (Erectile Dysfunction): A randomized clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/066866
Enrollment
60
Registered
2024-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N528- Other male erectile dysfunction

Interventions

None listed

Sponsors

Mahatma Gandhi Ayurved College Hospital and Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to participate in the study and give written informed consent.Patients with partial or complete erectile dysfunction reported with symptoms.Each mentioned a patient with IIEF identified sexual dysfunction.Patients having total testosterone level less than 249ng/mL

Exclusion criteria

Exclusion criteria: Current treatment with antihypertensive medication. Subject who have significant heart disease. History of neurological disorder. Homosexual person. History of penile trauma, injury, surgery. Subjects with history of significant central nervous system injuries (including stroke or spinal cord injury) within the last 6 month

Design outcomes

Primary

MeasureTime frame
Improvement in the levels of Sr TestosteroneTimepoint: 30 Days

Secondary

MeasureTime frame
Improvement in IIEF Questionnaire ScaleTimepoint: 30 Days

Countries

India

Contacts

Public ContactDr Sourabh Deshmukh

Mahatma Gandhi Ayurved College Hospital and Research Centre ,Salod Hirapur Wardha

Truptithakre555@gmail.com7020299894

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026